Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT

30 August 2025 (09:27 - 09:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?

Professor D. Bhatt (New York City, US)

Presentation thumbnail

Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis

Professor S. Mulvagh (Halifax, CA)

Abstract Slides Video

Presentation thumbnail

Efficacy of sotagliflozin among older adults: a pooled analysis of SCORED and SOLOIST-WHF

Doctor R. Aggarwal (Boston, US)

Abstract Slides Video

Presentation thumbnail

Undertreatment of women with lipid-lowering therapies in four European countries: results from the prospective, non-interventional MILOS Study

Professor I. Gouni-Berthold (Cologne, DE)

Abstract Slides Video

Access the full session

Session thumbnail

Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?

The Event

Event poster

ESC Congress 2025

30 August 2025 09:27 CET

You may be interested in

Congress Presentation

Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

Congress Presentation

Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT

Congress Presentation

Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources